Neurometrix, INC 8-K filings

NeuroMetrix, Inc. has been acquired by electroCore, Inc. through a merger completed on May 1, 2025, making NeuroMetrix a wholly-owned subsidiary of electroCore.

NeuroMetrix stockholders approved the merger agreement with electroCore at a special meeting held on March 21, 2025.

NeuroMetrix divests its DPNCheck product line assets for the Japanese market to Fukuda Denshi, securing an initial $400,000 payment and potential milestone payments up to $1.5 million.

NeuroMetrix, Inc. reports the resignation of Bradley Fluegel from the Board and Audit Committee, effective December 31, 2024, and the subsequent appointment of Joshua Horowitz to the Audit Committee.

NeuroMetrix has agreed to be acquired by electroCore, with shareholders receiving cash and contingent value rights.

NeuroMetrix's Q3 2024 results show a decline in overall revenue, primarily due to a decrease in DPNCheck sales, but also a significant increase in Quell revenue and reduced operating expenses.

NeuroMetrix reported a 54% decrease in revenue for Q2 2024 compared to Q2 2023, while also continuing its strategic review process.

NeuroMetrix held its annual stockholders meeting on April 30, 2024, electing two Class II directors and ratifying the appointment of Baker Tilly US, LLP as independent auditors.

NeuroMetrix has appointed Joshua Horowitz as a new independent director and terminated its at-the-market equity facility, following feedback from a major shareholder.

NeuroMetrix has modified the employment agreements of its CEO and CFO, allowing for temporary base salary reductions without impacting variable compensation calculations.

NeuroMetrix has extended its Shareholder Rights Agreement by one year, now expiring on March 8, 2025.

NeuroMetrix has extended its Shareholder Rights Agreement by one year, now expiring on March 8, 2025.

NeuroMetrix reported a decrease in revenue for Q4 and full year 2023, impacted by changes in Medicare Advantage reimbursements, while seeing growth in Quell Fibromyalgia.